FDMT
4D Molecular Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.22
+3.68%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$15.14
From 52W high−9.19%
Volume1.71M
Market cap$840.82M
P/E (TTM)—
P/S (TTM)9.1x
Div yield—
Key dataSep 18, 2026
Open
$15.14
From 52W high
−9.19%
Volume
1.71M
Market cap
$840.82M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
P/E (TTM)
—
RSI (14)
59.3
MomentumView details →
1D Return
+3.68%
YTD Return
+99.24%
SummaryUpdated Jun 1, 2026
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage gene therapy company founded in 2013 and headquartered in Emeryville, California. The company went public in December 2020 and focuses on developing innovative gene therapies using proprietary adeno-associated virus (AAV) vectors to treat rare genetic diseases. Since its founding, 4D Molecular has built a pipeline of gene therapy candidates targeting diseases in ophthalmology, cardiology, and pulmonology, with multiple programs currently in clinical trials.
Similar companies
Latest newsMore news →
Bank of America Corp DE increased its stake in 4D Molecular Therapeutics, Inc. by 17.0% during the first quarter, acquiring an additional 141,582 shares, according to a recent SEC filing.26d ago4D Molecular Therapeutics plans to initiate a Phase 3 trial for 4D-150 in diabetic macular edema in Q3 2026.37d ago4D Molecular Therapeutics completed enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 in wet AMD.83d ago